Ovarian cancer response to immunotherapy is limited; however, the evaluation of
sensitive/resistant target treatment subpopulations based on stratification by tumor …

Ovarian cancer is the third most common gynecologic malignancy worldwide but accounts
for the highest mortality rate among these cancers. A stepwise approach to assessment …

Background Homologous recombination deficiency (HRD) is a phenotype that is
characterized by the inability of a cell to effectively repair DNA double-strand breaks using …

Background In recurrent ovarian cancer, poly (ADP-ribose) polymerase (PARP)-inhibiting
agents have transformed the treatment of platinum-sensitive disease. New data support use …

Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. It is initially
responsive to cisplatin and carboplatin, two DNA damaging agents used in first line therapy …

Ovarian cancer (OC) remains a fatal malignancy because most patients experience
recurrent disease, which is resistant to chemotherapy. The outcomes for patients with …

Cellular senescence (CS), a state of permanent growth arrest, is intertwined with
tumorigenesis. Due to the absence of specific markers, characterizing senescence levels …

PARP inhibitors represent a major breakthrough in ovarian cancer care. Almost half of all
ovarian cancers have deficiencies in the homologous recombination (HR) DNA repair …

Purpose Several professional organizations recommend universal genetic assessment for
people with ovarian cancer as identifying pathogenic variants can affect treatment …

To improve our understanding of ovarian cancer, we performed genome-wide analyses of
45 ovarian cancer cell lines. Given the challenges of genomic analyses of tumors without …